Endocrine Society Shares ARPA-H Priorities

On August 3, Endocrine Society President Carol Wysham, MD, shared the Society’s recommendations and concerns about the proposal for a new federal agency, the Advanced Research Projects Agency for Health (ARPA-H) as part of a listening session with National Institutes of Health (NIH) Director Francis Collins.

Wysham highlighted diabetes as a prime example of a disease where treatment could be revolutionized through APRA-H-funded projects, and how ARPA-H could drive improvements in wearable devices for the measurement of a variety of parameters. She also encouraged the NIH and the White House Office on Science and Technology Policy (OSTP) leadership to ensure that equity is built into ARPA-H.

Endocrine Society President Carol Wysham, MD, (right) presents Endocrine Society comments on the development of ARPA-H at an NIH Listening Session attended by nearly 200 people as a sign language interpreter shares her message.

Collins appreciated our comments, in particular our remarks on the importance of health equity and shared some insight on how ARPA-H would select projects. Importantly, he noted that the project selection process is unlikely to involve external peer review, but instead would be guided by a series of questions describing the nature of the project and anticipated impact.

The Endocrine Society has been the only organization invited to present at more than one listening session, which reflects how endocrine science crosses multiple institutes at the NIH.

Previously, Endocrine Society President-Elect Ursula Kaiser, MD, presented our recommendations at a separate listening session focused on research related to the National Institute of Environmental Health Sciences (NIEHS). The Endocrine Society has been the only organization invited to present at more than one listening session, which reflects how endocrine science crosses multiple institutes at the NIH. It is unclear at this time how ARPA-H will advance, particularly because the federal appropriations process is at a standstill. We will continue to keep members apprised of new developments.

You may also like

  • August 2024 Endocrine Society Advocacy Update

    Revised Version of TROA Passes House Ways & Means Committee On June 27, 2024, the House Ways and Means Committee passed a revised version of the Treat and Reduce Obesity Act (TROA), legislation that would allow Medicare coverage of anti-obesity medications (AOMs), which currently is prohibited under law. The version that passed would only allow…

  • Endocrine Society Continues Global EDC Advocacy; EU Election Results Leaves Outcomes for EDC Legislation Uncertain  

    On June 17, the Endocrine Society joined delegations from dozens of countries gathered in Geneva, Switzerland, for the third session of an ad hoc open-ended working group (OEWG) convened under the United Nations Environment Programme (UNEP) to develop proposals to establish a new science policy panel charged with helping to inform governments, companies, farmers and…

Find more in